Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Mirum Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 Next >
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Presents New Data at The Liver Meeting®
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Present New Data at The Liver Meeting®
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.